Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension.

Seferian A, Jaïs X, Savale L, Jevnikar M, Ghighna MR, Weatherald J, Assoun S, Fadel E, Simonneau G, Sitbon O, Humbert M, Montani D.

Respir Med Res. 2019 Jul 9;76:48-53. doi: 10.1016/j.resmer.2019.06.002. [Epub ahead of print]

PMID:
31557688
2.

Home-Based Monitor for Gait and Activity Analysis.

Lilien C, Gasnier E, Gidaro T, Seferian A, Grelet M, Vissière D, Servais L.

J Vis Exp. 2019 Aug 8;(150). doi: 10.3791/59668.

PMID:
31449251
3.

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.

Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, Ropars J, Chouchane M, Cuppen I, Hughes I, Illingworth M, Marini-Bettolo C, Rambaud J, Taytard J, Annoussamy M, Scoto M, Gidaro T, Servais L.

Neurology. 2018 Oct 2;91(14):e1312-e1318. doi: 10.1212/WNL.0000000000006281. Epub 2018 Aug 29.

PMID:
30158155
4.

Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study.

Chabanon A, Seferian AM, Daron A, Péréon Y, Cances C, Vuillerot C, De Waele L, Cuisset JM, Laugel V, Schara U, Gidaro T, Gilabert S, Hogrel JY, Baudin PY, Carlier P, Fournier E, Lowes LP, Hellbach N, Seabrook T, Toledano E, Annoussamy M, Servais L; NatHis-SMA study group.

PLoS One. 2018 Jul 26;13(7):e0201004. doi: 10.1371/journal.pone.0201004. eCollection 2018.

5.

Rapid Contour-based Segmentation for 18F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation.

Besson FL, Henry T, Meyer C, Chevance V, Roblot V, Blanchet E, Arnould V, Grimon G, Chekroun M, Mabille L, Parent F, Seferian A, Bulifon S, Montani D, Humbert M, Chaumet-Riffaud P, Lebon V, Durand E.

Radiology. 2018 Jul;288(1):277-284. doi: 10.1148/radiol.2018171756. Epub 2018 Apr 3.

PMID:
29613842
6.

Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients.

Catapano F, Domingos J, Perry M, Ricotti V, Phillips L, Servais L, Seferian A, Groot I, Krom YD, Niks EH, Verschuuren JJ, Straub V, Voit T, Morgan J, Muntoni F.

Epigenomics. 2018 Jul;10(7):875-889. doi: 10.2217/epi-2018-0022. Epub 2018 Mar 22.

PMID:
29564913
7.

Dasatinib increases endothelial permeability leading to pleural effusion.

Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, Huertas A, Bezu JV, Breijer F, Vonk Noordegraaf A, Humbert M, Aman J, Guignabert C.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701096. doi: 10.1183/13993003.01096-2017. Print 2018 Jan.

8.

DMD and West syndrome.

Cardas R, Iliescu C, Butoianu N, Seferian A, Gataullina S, Gargaun E, Nectoux J, Bienvenu T, Craiu D, Gidaro T, Servais L.

Neuromuscul Disord. 2017 Oct;27(10):911-913. doi: 10.1016/j.nmd.2017.07.008. Epub 2017 Jul 19.

PMID:
28802771
9.

Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues.

Montani D, Seferian A, Parent F, Humbert M.

Eur Respir J. 2017 Aug 10;50(2). pii: 1701319. doi: 10.1183/13993003.01319-2017. Print 2017 Aug. No abstract available.

10.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

11.

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.

Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M.

Lancet Respir Med. 2017 Feb;5(2):125-134. doi: 10.1016/S2213-2600(16)30438-6. Epub 2017 Jan 11.

PMID:
28087362
12.

[Mitomycin-induced pulmonary veno-occlusive disease: A rare but severe complication].

Montani D, Chaumais MC, Seferian A, Humbert M.

Bull Cancer. 2017 Feb;104(2):202-204. doi: 10.1016/j.bulcan.2016.10.012. Epub 2016 Nov 21. French. No abstract available.

PMID:
27884394
13.

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.

Riou M, Seferian A, Savale L, Chaumais MC, Guignabert C, Canuet M, Magro P, Rea D, Sitbon O, Jaïs X, Humbert M, Montani D.

Eur Respir J. 2016 Nov;48(5):1517-1519. doi: 10.1183/13993003.01410-2016. Epub 2016 Oct 6. No abstract available.

14.

Mild clinical presentation in KLHL40-related nemaline myopathy (NEM 8).

Seferian AM, Malfatti E, Bosson C, Pelletier L, Taytard J, Forin V, Gidaro T, Gargaun E, Carlier P, Fauré J, Romero NB, Rendu J, Servais L.

Neuromuscul Disord. 2016 Oct;26(10):712-716. doi: 10.1016/j.nmd.2016.07.011. Epub 2016 Jul 29.

PMID:
27528495
15.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.

16.

A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment.

Le Moing AG, Seferian AM, Moraux A, Annoussamy M, Dorveaux E, Gasnier E, Hogrel JY, Voit T, Vissière D, Servais L.

PLoS One. 2016 Jun 7;11(6):e0156696. doi: 10.1371/journal.pone.0156696. eCollection 2016.

17.

EGR2 mutation enhances phenotype spectrum of Dejerine-Sottas syndrome.

Gargaun E, Seferian AM, Cardas R, Le Moing AG, Delanoe C, Nectoux J, Nelson I, Bonne G, Bihoreau MT, Deleuze JF, Boland A, Masson C, Servais L, Gidaro T.

J Neurol. 2016 Jul;263(7):1456-8. doi: 10.1007/s00415-016-8153-9. Epub 2016 May 9. No abstract available.

PMID:
27159987
18.

A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica.

Bourlier D, O'Connell C, Montani D, Savale L, Seferian A, Parent F, Humbert M, Simonneau G, Sitbon O, Jaïs X.

Eur Respir Rev. 2016 Mar;25(139):93-6. doi: 10.1183/16000617.0073-2015. No abstract available.

19.

Pulmonary complications of type 1 neurofibromatosis.

Reviron-Rabec L, Girerd B, Seferian A, Campbell K, Brosseau S, Bergot E, Humbert M, Zalcman G, Montani D.

Rev Mal Respir. 2016 Jun;33(6):460-73. doi: 10.1016/j.rmr.2014.09.010. Epub 2016 Feb 8. Review.

PMID:
26868668
20.

Chronic thromboembolic pulmonary hypertension.

O'Connell C, Montani D, Savale L, Sitbon O, Parent F, Seferian A, Bulifon S, Fadel E, Mercier O, Mussot S, Fabre D, Dartevelle P, Humbert M, Simonneau G, Jaïs X.

Presse Med. 2015 Dec;44(12 Pt 2):e409-16. doi: 10.1016/j.lpm.2015.10.010. Epub 2015 Nov 12. Review.

PMID:
26585271
21.

Pulmonary Hypertension Complicating Fibrosing Mediastinitis.

Seferian A, Steriade A, Jaïs X, Planché O, Savale L, Parent F, Amar D, Jovan R, Fadel E, Sitbon O, Simonneau G, Humbert M, Montani D.

Medicine (Baltimore). 2015 Nov;94(44):e1800. doi: 10.1097/MD.0000000000001800. Erratum in: Medicine (Baltimore). 2016 Jan;95(1):1. Medicine (Baltimore). 2016 Jan 08;95(1):e64cd.

22.

Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.

Montani D, Lau EM, Descatha A, Jaïs X, Savale L, Andujar P, Bensefa-Colas L, Girerd B, Zendah I, Le Pavec J, Seferian A, Perros F, Dorfmüller P, Fadel E, Soubrier F, Sitbon O, Simonneau G, Humbert M.

Eur Respir J. 2015 Dec;46(6):1721-31. doi: 10.1183/13993003.00814-2015. Epub 2015 Nov 5.

23.

Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.

Servais L, Montus M, Guiner CL, Ben Yaou R, Annoussamy M, Moraux A, Hogrel JY, Seferian AM, Zehrouni K, Le Moing AG, Gidaro T, Vanhulle C, Laugel V, Butoianu N, Cuisset JM, Sabouraud P, Cances C, Klein A, Leturcq F, Moullier P, Voit T.

J Neuromuscul Dis. 2015 Sep 2;2(3):269-279.

24.

Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial.

Seferian AM, Moraux A, Canal A, Decostre V, Diebate O, Le Moing AG, Gidaro T, Deconinck N, Van Parys F, Vereecke W, Wittevrongel S, Annoussamy M, Mayer M, Maincent K, Cuisset JM, Tiffreau V, Denis S, Jousten V, Quijano-Roy S, Voit T, Hogrel JY, Servais L.

PLoS One. 2015 Apr 10;10(4):e0121799. doi: 10.1371/journal.pone.0121799. eCollection 2015.

25.

Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.

Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, Le Moing AG, Gidaro T, Deconinck N, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Maincent K, Desguerre I, Thémar-Noël C, Cuisset JM, Tiffreau V, Denis S, Jousten V, Quijano-Roy S, Voit T, Hogrel JY, Servais L.

PLoS One. 2015 Feb 2;10(2):e0113999. doi: 10.1371/journal.pone.0113999. eCollection 2015.

26.

Pulmonary arterial hypertension in patients treated with interferon.

Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S, Jaïs X, Seferian A, Jovan R, Bulifon S, Parent F, Simonneau G, Humbert M, Sitbon O.

Eur Respir J. 2014 Dec;44(6):1627-34. doi: 10.1183/09031936.00057914. Epub 2014 Oct 16. Erratum in: Eur Respir J. 2015 Dec;46(6):1854.

27.

[Pulmonary hypertension: definition, diagnostic and new classification].

Seferian A, Simonneau G.

Presse Med. 2014 Sep;43(9):935-44. doi: 10.1016/j.lpm.2014.07.005. Epub 2014 Aug 12. Review. French.

PMID:
25127985
28.

Congenital muscular dystrophy phenotype with neuromuscular spindles excess in a 5-year-old girl caused by HRAS mutation.

Bolocan A, Quijano-Roy S, Seferian AM, Baumann C, Allamand V, Richard P, Estournet B, Carlier R, Cavé H, Gartioux C, Blin N, Le Moing AG, Gidaro T, Germain DP, Fardeau M, Voit T, Servais L, Romero NB.

Neuromuscul Disord. 2014 Nov;24(11):993-8. doi: 10.1016/j.nmd.2014.06.437. Epub 2014 Jun 28.

PMID:
25070542
29.

The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.

Steriade A, Seferian A, Jaïs X, Savale L, Jutant EM, Parent F, Sitbon O, Humbert M, Simonneau G, Montani D.

Ther Adv Respir Dis. 2014 Jun;8(3):84-92. Epub 2014 Apr 11.

PMID:
24728960
30.

Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.

Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, Thuillet R, Sattler C, Fadel E, Seferian A, Montani D, Dorfmüller P, Humbert M, Guignabert C.

Circulation. 2014 Apr 15;129(15):1586-97. doi: 10.1161/CIRCULATIONAHA.113.007469. Epub 2014 Jan 30.

PMID:
24481949
31.

Pathogenesis of pulmonary arterial hypertension: lessons from cancer.

Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D.

Eur Respir Rev. 2013 Dec;22(130):543-51. doi: 10.1183/09059180.00007513. Review.

32.

Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?

Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y, Humbert M, Montani D.

Semin Respir Crit Care Med. 2013 Oct;34(5):714-24. doi: 10.1055/s-0033-1356494. Epub 2013 Sep 13. Review.

PMID:
24037637
33.

Drug-induced pulmonary arterial hypertension: a recent outbreak.

Montani D, Seferian A, Savale L, Simonneau G, Humbert M.

Eur Respir Rev. 2013 Sep 1;22(129):244-50. doi: 10.1183/09059180.00003313. Review.

34.

Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?

Seferian A, Simonneau G.

Eur Respir Rev. 2013 Sep 1;22(129):217-26. doi: 10.1183/09059180.00001713. Review.

35.

Drugs induced pulmonary arterial hypertension.

Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M, Montani D.

Presse Med. 2013 Sep;42(9 Pt 2):e303-10. doi: 10.1016/j.lpm.2013.07.005. Epub 2013 Aug 22. Review.

PMID:
23972547
36.

Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats.

Bogdan S, Seferian A, Totoescu A, Dumitrache-Rujinski S, Ceausu M, Coman C, Ardelean CM, Dorobantu M, Bogdan M.

Maedica (Buchar). 2012 Jun;7(2):109-16.

37.

Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension.

Günther S, Jaïs X, Maitre S, Bérezné A, Dorfmüller P, Seferian A, Savale L, Mercier O, Fadel E, Sitbon O, Mouthon L, Simonneau G, Humbert M, Montani D.

Arthritis Rheum. 2012 Sep;64(9):2995-3005. doi: 10.1002/art.34501.

38.

Mediastinal fibrosis mimicking proximal chronic thromboembolic disease.

Seferian A, Jaïs X, Creuze N, Savale L, Humbert M, Sitbon O, Simonneau G, Montani D.

Circulation. 2012 Apr 24;125(16):2045-7. doi: 10.1161/CIRCULATIONAHA.111.058230. No abstract available.

PMID:
22529066
39.

Circulating fibrocytes and pulmonary arterial hypertension.

Gambaryan N, Cohen-Kaminsky S, Montani D, Girerd B, Huertas A, Seferian A, Humbert M, Perros F.

Eur Respir J. 2012 Jan;39(1):210-2. doi: 10.1183/09031936.00039811. No abstract available.

40.

Ventilation/perfusion lung scan in pulmonary veno-occlusive disease.

Seferian A, Helal B, Jaïs X, Girerd B, Price LC, Günther S, Savale L, Dorfmüller P, Parent F, Sitbon O, Humbert M, Simonneau G, Montani D.

Eur Respir J. 2012 Jul;40(1):75-83. doi: 10.1183/09031936.00097911. Epub 2011 Nov 16.

41.

Current management approaches to portopulmonary hypertension.

Savale L, O'Callaghan DS, Magnier R, Le Pavec J, Hervé P, Jaïs X, Seferian A, Humbert M, Simonneau G, Sitbon O.

Int J Clin Pract Suppl. 2011 Jan;(169):11-8. doi: 10.1111/j.1742-1241.2010.02600.x. Review.

PMID:
21176011

Supplemental Content

Loading ...
Support Center